Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

New treatments for macular degeneration may ... RGX-314 gene therapy only requires one injection, but it must be performed via a surgical procedure. This treatment is currently moving through ...

Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one. Macular degeneration, also known as age-related macular degeneration ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

discusses positive safety and efficacy data for NT-501 for macular telangiectasia type 2. NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals), an encapsulated cell therapy, was well ...